Search Results

Last Updated: July 29, 2026 TL;DR: Chile registers medicines through the Instituto de Salud Pública (ISP) under Decreto Supremo N°3 of 2010, using a five-module CTD dossier formally adopted in 2020, with a standard legal-evaluation timeline of roughly five to six months that can shorten to about three months for products already approved by a recognised high-surveillance authority. Chile is not currently a member, applicant or pre-applicant of the PIC/S GMP cooperation scheme - unlike Argentina, Brazil and Mexico in the same region - though ISP does auto-recognise bioequivalence findings from the US FDA and the Brazilian and Colombian authorities, and runs a separate reliance pathway for biological products. A locally established Titular or Representante Legal must hold the registration, since a foreign manufacturer cannot file directly. Chile has been a Hague Apostille Convention member since 2016 and operates a fast, digital e-Apostille register, so Indian certificates need only a single apostille rather than full consular legalisation - but Spanish-only labelling is strictly enforced. CENABAST, Chile's central procurement agency, runs public tenders that in 2026 explicitly include occasional-use injectable antimicrobials, against a backdrop of rising cardiovascular and cancer deaths, an ageing population, and a 2025 hospital-funding crisis that has already delayed oncology surgery and dialysis at at least one major public hospital for lack of paid suppliers. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and pharmaceuticals are already Chile's second-largest import category from India after vehicles, worth roughly US$200-218 million in 2024 under the standing India-Chile Preferential Trade Agreement. Key Takeaways Know the regulator and the realistic timeline. Chile's Instituto de Salud Pública (ISP), through its medicines department ANAMED, registers products under Decreto Supremo N°3 of 2010 using a five-module CTD dossier (formally adopted by ISP Resolution N°2232 in 2020). Standard legal evaluation runs roughly five to six months; an expedited track of about three months applies only to products already approved by a recognised high-surveillance authority, so confirm which track applies before committing to a delivery date. Chile sits outside PIC/S - a fact worth planning around, not ignoring. Unlike Argentina, Brazil and Mexico, Chile is not currently a PIC/S member, applicant or pre-applicant, so a WHO-GMP certificate alone is not automatically equivalent to a recognised-authority finding in every respect. ISP does auto-recognise bioequivalence approvals from the US FDA and the Brazilian and Colombian authorities, and runs a distinct reliance pathway for biological products, so a well-documented WHO-GMP dossier with a full site master file and inspection history remains the safest foundation. A local Titular is mandatory, and labelling must be Spanish-only. A foreign manufacturer cannot register directly in Chile: a Titular or Representante Legal established in the country, appointed by power of attorney, must hold the registration and act before ISP. Chile has been a Hague Apostille Convention member since 2016 with a fast digital e-Apostille system, so certificates need only a single apostille - but ISP actively enforces Spanish-only labelling, and has seized foreign-language-labelled products as recently as 2026. Demand is real, and current hospital-funding strain is a reliability opening. CENABAST's 2026 tender calendar explicitly includes occasional-use injectable antimicrobials and other injectables, cardiovascular disease and cancer are Chile's two leading causes of death and both rose again in 2024, and the population is ageing fast enough that over-65s will outnumber under-15s by 2028. A 2025 hospital-funding crisis already forced at least one major public hospital to delay oncology surgery and dialysis for lack of paid suppliers - exactly the kind of gap a dependable, well-documented supplier can fill. Introduction: Why an Injectable Manufacturer in Chile Must Meet Global Standards Chile runs one of Latin America's more procedurally mature medicines systems - a five-module CTD dossier, a named central procurement agency in CENABAST, and an e-Apostille system that makes cross-border documentation faster than in most emerging markets - yet the country still relies heavily on imports to meet hospital and pharmacy demand, and pharmaceuticals are already Chile's second-largest import category from India after vehicles. That import reliance sits inside a standing India-Chile Preferential Trade Agreement dating to 2007, with both governments now discussing a broader economic partnership that a November 2025 meeting specifically framed around simplifying medicine-registration processes. For an injectable manufacturer in Chile supply relationship, that combination of established trade infrastructure and continued import dependence is exactly the opening worth pursuing methodically rather than opportunistically. Global standards matter in Chile because the country's own procurement system is under visible strain. CENABAST's tender calendar for 2026 explicitly includes occasional-use injectable antimicrobials and other injectable lines, while a 2025 hospital-funding crisis - severe enough that Chile's Senate Health Committee held special sessions on it - left at least one major public hospital, Valparaíso's Carlos Van Buren, delaying oncology surgery and dialysis because suppliers had gone unpaid. In that environment, a manufacturer's reliability is as commercially valuable as its price: WHO-GMP certification, ISO Class 5 aseptic filling, complete certificates of analysis on every batch, and a registration secured well before a tender deadline are what separate a durable CENABAST or private-distribution relationship from a one-off shipment. What Sets a World-Class Injectable Manufacturer in Chile Apart The first differentiator is sterile manufacturing capability that stands on its own evidence, because Chile is not currently inside the PIC/S GMP cooperation scheme the way Argentina, Brazil and Mexico are. Farbe Firma runs its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic filling under unidirectional airflow, validated sterilisation and filtration, routine media fills and a documented contamination-control strategy across every production line, backed by a complete site master file and inspection history - the foundation ISP evaluation actually rests on in the absence of a PIC/S-based shortcut. The second differentiator is understanding the ISP pathway precisely. Registration runs under Decreto Supremo N°3 of 2010 through a five-module CTD dossier, with standard legal evaluation of roughly five to six months, shortened to about three months only for products already cleared by a recognised high-surveillance authority - worth confirming case by case rather than assuming the faster track applies. A foreign manufacturer cannot file directly: a Titular or Representante Legal established in Chile, appointed by power of attorney, must hold the registration. Certificates need only a single apostille, since Chile has been a Hague Convention member since 2016 with a fast digital e-Apostille register - genuinely convenient - but labelling must be Spanish-only; ISP has enforced this as recently as 2026 by seizing foreign-language-labelled stock. Quality Systems Behind Every Batch We Ship to Chile Every Farbe Firma injectable batch destined for Chile is released only once the full analytical stack has been completed and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer for lyophilised presentations; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality and fill-volume uniformity to compendial limits on every ampoule and vial format. Batch records, deviation reports and any out-of-specification investigations are reviewed by qualified persons before release, and a retained sample of every batch is held for its full shelf life so that any question raised by ISP, a Titular or a CENABAST tender evaluator can be traced back to source. Behind release testing sits the stability programme that supports the dossier itself. Stability runs on three batches under long-term, intermediate and accelerated conditions per ICH Q1A, with photostability per ICH Q1B. Chile is conventionally classified in ICH Climatic Zone II (25°C/60% relative humidity) for filing purposes, consistent with regional practice for Argentina, Peru and Uruguay, though we always confirm the specific conditions ISP's Norma Técnica N°129 expects for a given product rather than assume the general convention applies without exception. Given Chile's genuinely varied climate, from the Atacama Desert in the north to Patagonia in the south, we build in shipping and storage guidance appropriate to the distribution route rather than a single blanket assumption. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Chile for Global Buyers Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, and obstetric and life-saving products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. For Chile that maps directly onto the country's health profile: injectable cardiovascular and emergency-care medicines against a disease burden that caused over 32,000 deaths in 2024 alone, oncology-supportive and anaesthetic injectables for a cancer burden that killed more than 31,000 people the same year, and the broader anaesthesia and analgesic range an ageing population needs in growing volume as over-65s are projected to outnumber under-15s by 2028. Our CDMO services scale from a single distributor's launch portfolio to full CENABAST tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, Spanish-language artwork development, and regulatory dossiers compiled to the five-module CTD format for ISP submission through your Titular. We supply WHO-format certificates of pharmaceutical product, WHO-GMP certification, site master files, per-batch certificates of analysis against IP, BP, USP or EP monographs, and apostilled document packages under Chile's digital e-Apostille system. For institutional supply, we support partners preparing for CENABAST's Mercado Público tender process, including the 2026 tender line that explicitly covers occasional-use injectable antimicrobials and other injectables. Buyers stay with Farbe Firma because we are direct about what actually determines success in Chile, and right now that includes an unusually candid point: Chilean hospitals themselves are under financial strain. Chile's Senate Health Committee held special sessions in 2025 on a hospital-funding crisis that left Valparaíso's Carlos Van Buren Hospital delaying oncology surgery and dialysis because suppliers had gone unpaid, and ISP maintains a live shortage tracker that reflects the same pressure. In that environment, a supplier that ships on schedule, documents completely and prices predictably is worth more than one offering the lowest headline price. Logistically, transit from India's west-coast ports to Valparaíso runs on the order of a month depending on routing via Suez and the Panama Canal or, when conditions require, the longer Cape of Good Hope route, so we build realistic transit time and generous residual shelf life into every Chile-bound quote rather than promising a delivery window we cannot consistently meet. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Chile? Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Chile we provide the documentation ISP's evaluation requires: a five-module CTD dossier, a WHO-format certificate of pharmaceutical product, a WHO-GMP certificate, the site master file, per-batch certificates of analysis against BP, USP, IP or EP monographs, and ICH Q1A stability data. We also prepare the apostilled document set and Spanish-language labelling and artwork your Chilean Titular needs to lodge the application. How does drug registration work in Chile, and is Chile part of PIC/S? Registration is administered by the Instituto de Salud Pública (ISP) through its medicines department ANAMED, under Decreto Supremo N°3 of 2010, using a five-module CTD dossier formally adopted by ISP Resolution N°2232 in 2020. Standard legal evaluation takes roughly five to six months, shortened to about three months only for products already approved by a recognised high-surveillance authority. Chile is not currently a member, applicant or pre-applicant of the PIC/S GMP cooperation scheme, unlike Argentina, Brazil and Mexico in the same region, so we recommend building the submission on complete WHO-GMP evidence - full site master file and inspection history - rather than assuming an automatic reliance shortcut, while noting that ISP does separately auto-recognise FDA, Brazilian and Colombian bioequivalence findings and runs a dedicated reliance pathway for biological products. Do we need a local partner to register and import injectables in Chile? Yes. A foreign manufacturer cannot register directly with ISP: a Titular or Representante Legal established in Chile, appointed by power of attorney, must hold the registration and act on the manufacturer's behalf throughout the process. Farbe Firma supplies the manufacturer-side package - CTD dossier, certificate of pharmaceutical product, GMP certificate, site master file, certificates of analysis, letters of authorisation and Spanish-language artwork, together with the apostilled versions Chile's Hague Convention membership allows - while your Chilean Titular holds the registration and manages the ISP-facing process. Which injectables are in strongest demand in Chile? Cardiovascular and oncology-supportive care lead. Cardiovascular disease was Chile's leading cause of death in 2024 with over 32,000 deaths, up 7.5% on 2023, and cancer killed more than 31,000 people the same year - both figures from official MINSAL/DEIS mortality data. CENABAST's 2026 public-tender calendar explicitly includes occasional-use injectable antimicrobials and other injectables, and an ageing population - over-65s are projected to outnumber under-15s by 2028 - keeps demand growing for the broader anaesthesia, analgesic and emergency-care injectable range that every hospital needs as routine stock. What are the real documentation, apostille and logistics considerations for shipping injectables to Chile? The three factors that most shape a Chile launch are apostille versus legalisation, Spanish-only labelling, and realistic sea-freight timing. Chile has been a Hague Apostille Convention member since 2016 and runs a fast digital e-Apostille register, so certificates need only a single apostille step rather than full consular legalisation - genuinely convenient compared with many export markets. Labelling must be Spanish-only; ISP has actively enforced this, seizing foreign-language-labelled products as recently as 2026, so plan Spanish artwork from the outset rather than translating late. On logistics, transit from India's west-coast ports to Valparaíso or San Antonio runs on the order of a month depending on routing via Suez and the Panama Canal or the longer Cape of Good Hope route, so build realistic transit buffers and generous residual shelf life into any CENABAST tender delivery commitment. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: July 29, 2026 TL;DR: Kazakhstan registers medicines through the Eurasian Economic Union's unified procedure, mandatory for new dossiers since January 2021, using an EAEU Common Technical Document format reviewed by a reference-state authority together with one or more recognition states, typically inside a ceiling of roughly 300 calendar days. In April 2026 the World Health Organization designated Kazakhstan a Maturity Level 3 regulatory authority, the first in Central Asia and the CIS and only the fourth in the WHO European Region - a genuine credibility marker, though it does not create an automatic reliance route for non-EAEU manufacturers, whose dossiers still need strong WHO-GMP inspection evidence and a complete site master file. A foreign manufacturer cannot file alone: the Applicant, the Authorized Representative and the pharmacovigilance contact must all be established inside the EAEU. Kazakhstan has been a Hague Apostille Convention member since 2001, so certificates need only a single apostille rather than full consular legalisation, though dossiers and labelling must be bilingual in Kazakh and Russian. SK-Pharmacy, the state's single distributor, runs centralised tenders for over 1,200 hospitals and 700 polyclinics, and despite meaningful domestic ampoule capacity at SANTO/Chimpharm, roughly 85% of pharmaceutical value is still imported. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and pharmaceutical formulations already rank among India's largest single export categories to Kazakhstan. Key Takeaways Know the regulatory pathway: EAEU, not a purely national route. Since January 2021, new marketing-authorisation applications in Kazakhstan go through the Eurasian Economic Union's unified procedure rather than a standalone national process, using an EAEU Common Technical Document harmonised with the ICH CTD and reviewed by a 'reference state' plus one or more 'recognition states', inside a ceiling of roughly 300 calendar days. Legacy national certificates are being phased out with grandfathered extensions, so confirm current transition status at filing time. WHO Maturity Level 3 raises the bar, but doesn't remove the paperwork. In April 2026, WHO designated Kazakhstan's regulatory system Maturity Level 3 - the first in Central Asia and the CIS - which strengthens confidence in the authority itself, but non-EAEU manufacturers still need to submit strong WHO-GMP inspection evidence, a complete site master file and recent inspection reports for every manufacturing site rather than assume any blanket automatic-recognition shortcut. A local EAEU-based representative is mandatory. The Marketing Authorisation Holder itself can be a non-resident, but the Applicant who files the dossier, the Authorized Representative, and the pharmacovigilance contact (QPPV) must all be a legal entity or individual entrepreneur established inside the EAEU - in Kazakhstan or elsewhere in the bloc. Apostille, not full consular legalisation, applies to supporting certificates, since Kazakhstan has been a Hague Convention member since 2001 - genuinely simpler than most African and Middle Eastern markets - but every dossier, label, leaflet and summary of product characteristics must be bilingual in Kazakh and Russian. Demand is real, tender-driven and only partly met locally. SK-Pharmacy, the state's 100%-owned single distributor, runs centralised public tenders supplying more than 1,200 hospitals and 700 polyclinics from a catalogue of over 1,500 products. Kazakhstan met the WHO 2025 target for reducing premature non-communicable-disease mortality - the first Central Asian country to do so - reflecting a growing cardiovascular and emergency-care caseload, and even though SANTO/Chimpharm supplies meaningful domestic ampoule volumes, roughly 85% of pharmaceutical value nationally is still imported. Introduction: Why an Injectable Manufacturer in Kazakhstan Must Meet Global Standards Kazakhstan's pharmaceutical market has changed structurally since January 2021, when the country's medicines registration moved onto the Eurasian Economic Union's unified procedure alongside Russia, Belarus, Armenia and Kyrgyzstan. New dossiers are now built to the EAEU Common Technical Document format and reviewed under a reference-state and recognition-state model, and in April 2026 the World Health Organization designated Kazakhstan's own regulatory system Maturity Level 3 - the first in Central Asia and the CIS, and only the fourth in the entire WHO European Region. That milestone raises the credibility bar for the whole market rather than lowering the entry bar for foreign suppliers: it signals that SK-Pharmacy tenders, hospital procurement and private distributors alike now operate against a more rigorous domestic reference point. Against that backdrop, pharmaceutical formulations already sit among India's largest single export categories to Kazakhstan, and bilateral trade sits well below the roughly US$3 billion target both governments have floated - which is exactly the kind of gap a serious injectable manufacturer in Kazakhstan supply relationship can help close. Global standards matter here because Kazakhstan, unlike some newer export markets, already has a domestic reference point to compare a foreign supplier against: SANTO/Chimpharm alone reportedly produces on the order of 300 million ampoules a year. That means an entrant is not filling a total capability vacuum - it is competing on documentation rigor, EAEU dossier compliance, and reliability against a market that already understands what a well-run sterile line looks like. For an exporter, the practical takeaway is the one that recurs in every serious market: WHO-GMP certification, ISO Class 5 aseptic filling, validated analytical release testing, and - specific to Kazakhstan - a properly structured EAEU dossier filed through a locally established Authorized Representative, are what separate a durable SK-Pharmacy or private-distribution relationship from a shipment that stalls in registration. What Sets a World-Class Injectable Manufacturer in Kazakhstan Apart The first differentiator is sterile manufacturing capability that holds up against both EAEU reviewers and a domestic industry that already knows the standard. Farbe Firma runs its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic filling under unidirectional airflow, validated sterilisation and filtration, routine media fills and a documented contamination-control strategy across every production line. That matters in Kazakhstan specifically because the country's own regulator reached WHO Maturity Level 3 in April 2026, meaning EAEU dossier reviewers are working to a demonstrably higher international benchmark than a few years ago - a supplier's documentation has to be equally rigorous, not just adequate. The second differentiator is understanding the EAEU pathway precisely rather than assuming it works like a purely national registration. Since January 2021, new applications go through the EAEU's unified procedure: an EAEU Common Technical Document dossier, reviewed by a reference-state authority together with one or more recognition states, generally inside a ceiling of around 300 calendar days, with GMP conformity assessed for every manufacturing site named in the dossier, including non-EAEU sites like Gujarat. Just as important is who can file: the Applicant, the Authorized Representative and the pharmacovigilance contact must all be a legal entity or individual entrepreneur established inside the EAEU, even though the Marketing Authorisation Holder itself can remain a non-resident. Certificates need only a single apostille, since Kazakhstan has been a Hague Convention member since 2001 - simpler than the full consular legalisation many neighbouring markets require - but every dossier, label and leaflet must be bilingual in Kazakh and Russian from the outset. Quality Systems Behind Every Batch We Ship to Kazakhstan Every Farbe Firma injectable batch destined for Kazakhstan is released only once the full analytical stack has been completed and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer for lyophilised presentations; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality and fill-volume uniformity to compendial limits on every ampoule and vial format. Batch records, deviation reports and any out-of-specification investigations are reviewed by qualified persons before release, and a retained sample of every batch is held for its full shelf life so that any question raised during EAEU dossier review or by a Kazakhstani distributor can be traced back to source. Behind release testing sits the stability programme that supports the dossier itself. Stability runs on three batches under long-term, intermediate and accelerated conditions per ICH Q1A, with photostability per ICH Q1B. Kazakhstan's continental climate is generally classified in ICH Zone I to Zone II for filing purposes - materially milder than the hot-humid Zone IVb conditions used for tropical and coastal markets - though we always confirm the specific storage conditions a given EAEU reference-state reviewer expects rather than assume a single default zone applies to every product. We hold stability data across the relevant range so a dossier can be built to whichever condition the reviewing authority requires. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Kazakhstan for Global Buyers Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, and obstetric and life-saving products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. For Kazakhstan that maps directly onto the country's health priorities: injectable cardiovascular and emergency-care medicines against a non-communicable-disease burden that drives roughly 90% of deaths regionally even after Kazakhstan became the first Central Asian country to meet the WHO 2025 target for reducing premature NCD mortality, anti-infectives supporting a tuberculosis caseload still running near 70 per 100,000 people, and the broad anaesthesia, analgesic and hospital-injectable range that SK-Pharmacy's tender catalogue of more than 1,500 products draws on every year. Our CDMO services scale from a single distributor's launch portfolio to full SK-Pharmacy tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, bilingual Kazakh-and-Russian artwork development, and regulatory dossiers compiled to the EAEU Common Technical Document format for submission through a locally established Authorized Representative. We supply WHO-format certificates of pharmaceutical product, WHO-GMP certification, site master files, per-batch certificates of analysis against IP, BP, USP or EP monographs, and apostilled document packages, since Kazakhstan's 2001 accession to the Hague Convention means a single apostille - not full consular legalisation - is all the documentation chain requires. For institutional supply, we help partners prepare the technical file SK-Pharmacy's centralised tenders expect, alongside the private wholesale channel that still carries a large share of the roughly 85% of pharmaceutical value Kazakhstan imports. Buyers stay with Farbe Firma because we are straightforward about what actually shapes a Kazakhstan launch, and it is regulatory structure more than tariff cost. The two workstreams worth starting immediately, in parallel with dossier compilation rather than after it, are appointing an EAEU-established Authorized Representative and QPPV to hold the filing, and preparing bilingual Kazakh-and-Russian labelling and artwork from day one rather than translating late. Kazakhstan is landlocked, so realistic logistics planning matters as much as regulatory planning: cargo typically moves via the Middle Corridor through the South Caucasus and the Caspian Sea to Aktau or Kuryk, via the INSTC's eastern route through Iran, or via China's Khorgos crossing, and every one of those corridors runs to several weeks door-to-door, so quote generous residual shelf life and build transit buffers into any SK-Pharmacy tender delivery commitment rather than assuming a single fast route. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Kazakhstan? Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Kazakhstan we provide the documentation an EAEU dossier requires: an EAEU Common Technical Document-format dossier, a WHO-format certificate of pharmaceutical product, a WHO-GMP certificate, the site master file, per-batch certificates of analysis against BP, USP, IP or EP monographs, and ICH Q1A stability data. We also prepare the apostilled document set and bilingual Kazakh-and-Russian labelling and artwork your Kazakhstani Authorized Representative needs to lodge the application. How does drug registration work in Kazakhstan now that it is inside the EAEU? Since January 2021, new marketing-authorisation applications in Kazakhstan go through the Eurasian Economic Union's unified procedure rather than a purely national one, using an EAEU Common Technical Document dossier reviewed by a 'reference state' together with one or more 'recognition states', generally inside a ceiling of around 300 calendar days. Legacy national certificates are being phased out with grandfathered extensions of up to two or three years depending on the pathway, so we recommend confirming the current transition status with your Authorized Representative at filing time. In April 2026, WHO designated Kazakhstan's regulatory system Maturity Level 3 - the first in Central Asia and the CIS - which raises confidence in the authority itself without creating an automatic recognition shortcut for non-EAEU manufacturing sites. Do we need a local partner to register and import injectables in Kazakhstan? Yes. While the Marketing Authorisation Holder itself can be a non-resident company, the Applicant who files the dossier, the Authorized Representative, and the pharmacovigilance contact (QPPV) must all be a legal entity or individual entrepreneur established inside the EAEU - in Kazakhstan or elsewhere in the bloc. Farbe Firma supplies the manufacturer-side package - EAEU CTD dossier, certificate of pharmaceutical product, GMP certificate, site master file, certificates of analysis, letters of authorisation and bilingual Kazakh-and-Russian artwork, together with the apostilled versions Kazakhstan's Hague Convention membership allows - while your Kazakhstani Authorized Representative holds the filing and manages the registration process. Which injectables are in strongest demand in Kazakhstan? Cardiovascular and emergency-care medicines lead, reflecting a non-communicable-disease burden that drives around 90% of deaths regionally even after Kazakhstan became the first Central Asian country to meet the WHO 2025 target for reducing premature NCD mortality - the country expanded its catheterisation-lab network from 31 to 49 sites and established 83 emergency stroke centres between 2017 and 2024. Tuberculosis incidence, while declining, still runs near 70 cases per 100,000 people, sustaining demand for injectable anti-infectives, and SK-Pharmacy's centralised tender catalogue of more than 1,500 products spans the full hospital range from anaesthetics and analgesics to obstetric and emergency injectables across more than 1,200 hospitals and 700 polyclinics. What are the real documentation, language and logistics considerations for shipping injectables to Kazakhstan? The three factors that most shape a Kazakhstan launch are the EAEU filing structure, bilingual labelling, and landlocked logistics - not the tariff line. Kazakhstan has been a Hague Apostille Convention member since 2001, so certificates need only a single apostille rather than full consular legalisation, which is genuinely simpler than many other export markets. Dossiers, labels and leaflets must be bilingual in Kazakh and Russian from the outset, not translated late. On logistics, Kazakhstan is landlocked, and cargo from India typically routes via the Middle Corridor through the Caspian Sea to Aktau or Kuryk, via the INSTC's eastern corridor through Iran, or via China's Khorgos crossing - every corridor runs to several weeks door-to-door, so build realistic transit buffers and generous residual shelf life into any tender delivery commitment. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Last Updated: July 28, 2026 TL;DR: Zambia imports an estimated 80-90% of the medicines it consumes, and India already supplies more than 46% of those pharmaceutical imports by value - yet sterile injectable manufacturing capacity inside the country remains minimal. The regulator is the Zambia Medicines Regulatory Authority (ZAMRA), established under the Medicines and Allied Substances Act No. 3 of 2013, which reviews marketing-authorisation dossiers in CTD format and aligns its technical standards with WHO-GMP, though it has not yet been benchmarked at WHO Global Benchmarking Tool Maturity Level 3. Registration runs for five years and must be filed through a locally registered wholesale dealer or regulatory agent, since ZAMRA does not issue a marketing authorisation directly to a foreign manufacturer. Zambia has not ratified the Hague Apostille Convention, so certificates of pharmaceutical product, GMP certificates and powers of attorney require full consular legalisation rather than a single apostille stamp. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and builds Zambia-ready CTD dossiers, consular-legalised documentation and Climatic Zone II-appropriate stability packages for importers supplying ZAMMSA tenders and the private wholesale market. Key Takeaways Know the regulator and its real standing. Zambia's national medicines authority is ZAMRA, created under the Medicines and Allied Substances Act No. 3 of 2013. ZAMRA reviews marketing-authorisation dossiers in CTD format and references WHO-GMP standards in its own guidance, but it has not yet been benchmarked at WHO Global Benchmarking Tool Maturity Level 3, and no PIC/S membership or applicant status is confirmed. Build the dossier on solid WHO-GMP evidence rather than assuming an automatic reliance shortcut. A local partner is mandatory, not optional. ZAMRA does not register a product in the name of a foreign manufacturer: the marketing authorisation must be filed through a Zambian-registered wholesale dealer or regulatory agent operating under a pharmacist registered with the Pharmaceutical Society of Zambia. That local partner holds the certificate, lodges each import application and carries the ongoing compliance obligations once the product is on the market. Get the legalisation chain right, not the apostille shortcut. Zambia has not ratified the 1961 Hague Apostille Convention. Certificates of pharmaceutical product, GMP certificates, free-sale certificates and powers of attorney all require full consular legalisation - notarisation, home-country authentication, then legalisation at the Zambian High Commission or embassy - before ZAMRA and Zambian customs will accept them. Demand is real and structurally import-dependent. Zambia produces only an estimated 10-20% of the medicines it consumes, with 80-90% imported and only a handful of the country's ten registered manufacturers actively operating; sterile injectable capacity among them is minimal. India already supplies more than 46% of Zambia's pharmaceutical imports by value, and ZAMMSA's tender pipeline serves over 2,600 public health facilities, with national essential-medicine availability having climbed from about 35% in 2021 to over 80% in 2024. Introduction: Why an Injectable Manufacturer in Zambia Must Meet Global Standards Zambia imports somewhere between 80% and 90% of the medicines it consumes, and only around 123 locally produced medicines were registered out of more than 8,000 total products on ZAMRA's own 2022 count. Of the country's roughly ten registered pharmaceutical manufacturers, only about four were confirmed actively operating, led by Pharmanova in Lusaka, which focuses on tablets, oral liquids and basic parenteral lines rather than a broad sterile injectable portfolio. Against that backdrop, India already supplies more than 46% of Zambia's pharmaceutical imports by value, ahead of every other source country, and Indian pharmaceutical exports to Zambia grew roughly 49% to reach US$90.57 million in 2024. Sterile injectables sit squarely in the gap between what Zambia's own manufacturers can produce and what its hospitals, clinics and tenders actually need - and that gap is the commercial opening for any serious injectable manufacturer in Zambia supply relationship. Global standards matter because Zambian buyers, like buyers across the region, increasingly ask for proof rather than a sales pitch. ZAMMSA - the Zambia Medicines and Medical Supplies Agency, formed in February 2021 to replace the former Medical Stores Limited - now runs the national warehouse and distribution system for more than 2,600 public health facilities, and its tenders are won on documentation as much as price: a valid ZAMRA marketing authorisation, a WHO-GMP certificate, and per-batch certificates of analysis are the baseline, not an extra. For an exporter, the lesson is the same one that recurs across every serious African market: WHO-GMP certification, ISO Class 5 aseptic filling, validated analytical release testing and a registration secured before the container leaves port are what separate a durable supply relationship from a single opportunistic shipment. What Sets a World-Class Injectable Manufacturer in Zambia Apart The first differentiator is sterile manufacturing capability that holds up under scrutiny from both ZAMRA and the tender committees at ZAMMSA. Farbe Firma runs its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic filling under unidirectional airflow, validated sterilisation and filtration, routine media fills and a documented contamination-control strategy across every production line. That standard matters in Zambia specifically because local manufacturing capacity for sterile parenterals is close to non-existent - the domestic industry's strength lies in oral solids and liquids, not aseptically filled ampoules and vials - so buyers have no domestic fallback if an import consignment fails on quality. The second differentiator is knowing the ZAMRA pathway precisely rather than assuming it mirrors a neighbouring country. Registration follows the CTD format under ZAMRA's own published guidance, marketing authorisation is valid for five years before renewal, and - critically - a foreign manufacturer cannot register directly: the application must be filed through a Zambian-registered wholesale dealer or regulatory agent supervised by a locally registered pharmacist. Equally important is the legalisation chain: Zambia has not signed the Hague Apostille Convention, so certificates of pharmaceutical product, GMP certificates and powers of attorney need full consular legalisation through the Zambian High Commission rather than the single-step apostille that neighbouring Apostille-member states like South Africa, Botswana, Namibia and Malawi accept. Treating Zambia as an apostille market is a documented, avoidable filing error. Quality Systems Behind Every Batch We Ship to Zambia Every Farbe Firma injectable batch destined for Zambia is released only once the full analytical stack has been completed and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer for lyophilised presentations; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality and fill-volume uniformity to compendial limits on every ampoule and vial format. Batch records, deviation reports and any out-of-specification investigations are reviewed by qualified persons before release, and a retained sample of every batch is held for the full shelf life so any query raised in the Zambian market can be traced back to source. Behind release testing sits the stability programme that supports the dossier itself. Stability runs on three batches under long-term, intermediate and accelerated conditions per ICH Q1A, with photostability per ICH Q1B. Zambia's high-altitude plateau climate - Lusaka sits at roughly 1,280 metres - places the country in ICH Climatic Zone II rather than the hot-humid Zone IVb that buyers often assume applies across Sub-Saharan Africa; Zone II conditions run at 25°C/60% relative humidity for long-term data and 30°C/65% relative humidity accelerated, milder than the 30°C/75% conditions used for coastal and lowland neighbours. Filing against the correct zone avoids both an unnecessary over-engineering of the stability package and a mismatch that a ZAMRA reviewer would flag on inspection. Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry Why Farbe Firma is the Trusted Injectable Manufacturer in Zambia for Global Buyers Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, and obstetric and life-saving products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. For Zambia that maps directly onto the country's disease burden: injectable antimalarials and antibiotics against a malaria caseload that Zambian Ministry of Health data put at over 11 million cases in 2023, injectable antiretrovirals and anti-infectives supporting a national HIV programme covering roughly 1.3 million people living with HIV, IV fluids and antibiotics for the cholera outbreaks that recurred in Lusaka in 2023-2024 and again in Mpulungu District in 2025, and the oxytocin, tranexamic acid and magnesium sulphate that every maternity ward keeps on hand. Our CDMO services scale from a single distributor's launch portfolio to full ZAMMSA tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, artwork development and regulatory dossiers compiled to CTD format for ZAMRA submission. We supply WHO-format certificates of pharmaceutical product, WHO-GMP certification, site master files, per-batch certificates of analysis against IP, BP, USP or EP monographs, and English-language artwork with space reserved for the ZAMRA registration number once granted. For public-sector work, we help partners prepare the documentation ZAMMSA's tender process expects, given that its warehouse network now supplies more than 2,600 facilities and national essential-medicine availability has risen from roughly 35% in 2021 to over 80% in 2024 - a genuine, fast-growing market rather than a stagnant one. Buyers stay with Farbe Firma because we are direct about what actually slows a Zambian launch down, and it is rarely the tariff line. The real friction points are procedural: securing a locally registered wholesale dealer or regulatory agent to hold the marketing authorisation, completing full consular legalisation rather than a faster apostille, and building the stability package to the correct Zone II conditions rather than defaulting to Zone IVb. Logistically, Zambia is landlocked, and cargo typically routes through the ports of Durban or Dar es Salaam before road or rail transit inland, so realistic door-to-door planning from India runs several weeks and should be built into tender timelines rather than assumed away. Our consistent advice is to start the local-partner and legalisation workstreams in parallel with dossier compilation, not sequentially after it, and to quote generous residual shelf life against ZAMMSA's delivery expectations. Explore Farbe Firma: Products | Global Reach | About Us Frequently Asked Questions (FAQ) Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Zambia? Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Zambia we provide the documentation ZAMRA and ZAMMSA expect: a CTD-format dossier, a WHO-format certificate of pharmaceutical product, a WHO-GMP certificate, the site master file, per-batch certificates of analysis against BP, USP, IP or EP monographs, ICH Q1A stability data filed to the correct Climatic Zone II conditions, and English-language artwork with space reserved for the ZAMRA registration number. We also prepare the fully consular-legalised document set your Zambian partner needs to lodge the application, since Zambia does not accept a simple apostille. How does ZAMRA registration work, and how long does it take? ZAMRA, the Zambia Medicines Regulatory Authority, was established under the Medicines and Allied Substances Act No. 3 of 2013 and reviews marketing-authorisation applications in CTD format, referencing WHO-GMP standards in its technical guidance. A granted marketing authorisation is valid for five years before renewal is required. ZAMRA has not yet been benchmarked at WHO Global Benchmarking Tool Maturity Level 3, and no confirmed PIC/S membership exists, so we recommend building the submission on strong, complete WHO-GMP evidence rather than assuming an automatic reliance route will shorten the timeline. Because ZAMRA does not publish a single guaranteed end-to-end processing time in the sources available to us, we advise confirming the current expected timeline directly with ZAMRA or your local regulatory agent before committing to a tender delivery date. Do we need a local partner or licence to import injectables into Zambia? Yes, and this is not optional. ZAMRA does not issue a marketing authorisation directly to a foreign manufacturer; the application must be filed through a Zambian-registered wholesale dealer or regulatory agent operating under a pharmacist registered with the Pharmaceutical Society of Zambia. That local partner holds the marketing authorisation, applies for each import consignment and carries the ongoing regulatory obligations once the product is in the market. Farbe Firma supplies the manufacturer-side package - CTD dossier, certificate of pharmaceutical product, GMP certificate, site master file, certificates of analysis, letters of authorisation and artwork, together with the fully consular-legalised versions Zambia requires - while your Zambian partner holds the licence and manages the ZAMRA and, where relevant, ZAMMSA-facing process. Which injectables are in strongest demand in Zambia? Malaria, HIV and outbreak response dominate. Zambian Ministry of Health data reported more than 11 million malaria cases in 2023, up sharply year on year, sustaining strong demand for injectable antimalarials alongside the oral artemisinin-based therapies used more widely. Zambia also carries one of the highest HIV prevalence rates in the world, at around 11% of the adult population and roughly 1.3 million people living with HIV, which drives steady demand for injectable anti-infectives supporting opportunistic-infection management. Cholera outbreaks in Lusaka in 2023-2024 and in Mpulungu District in 2025 pushed sharp, episodic demand for IV fluids and injectable antibiotics, and every maternity and emergency department needs oxytocin, tranexamic acid, magnesium sulphate, adrenaline and the broader anaesthesia and analgesic range that underpins routine hospital care. What are the real documentation, climatic-zone and logistics considerations for shipping injectables to Zambia? The three things that most often trip up a first-time exporter to Zambia are legalisation, climatic zone and inland logistics - not the tariff schedule itself. Zambia has not ratified the Hague Apostille Convention, so certificates of pharmaceutical product, GMP certificates and powers of attorney require full consular legalisation through the Zambian High Commission rather than a one-step apostille, and that chain takes materially longer to complete than an apostille does. On stability, Zambia's high-altitude plateau climate places it in ICH Climatic Zone II (25°C/60% RH long-term, 30°C/65% RH accelerated) rather than the hot-humid Zone IVb that many buyers assume applies across Sub-Saharan Africa, so filing to the correct zone both satisfies ZAMRA's expectations and avoids unnecessary formulation cost. On logistics, Zambia is landlocked, and consignments typically transit through the ports of Durban or Dar es Salaam before road or rail movement inland, so build several weeks of realistic door-to-door transit time into any ZAMMSA tender delivery commitment. Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert) Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA Request a Quote | View Products | FAQ | Blog

Browse 245+ WHO-GMP sterile injectable formulations from Farbe Firma — strengths, packing & therapeutic categories. Bulk export & dossier support. Formulation List Therapeutic Category Filter by Product Name Alpha Beta Arteether Injection 75 mg/ml 1 ml, 2 ml, 3 ml Antimalarials & Antiprotozoals https://www.farbefirma.org/product/alpha-beta-arteether-injection Read More Amikacin Sulphate Injection 250 mg/ml 2 ml Antibiotics https://www.farbefirma.org/product/amikacin-sulphate-injection Read More Analgin Injection (Metamizole/Dipyrone) 100 mg/ml 2 ml, 5 ml Antihistamines / Antiallergics / Antiasthmatic https://www.farbefirma.org/product/analgin-injection Read More Artemether Injection 40 mg/ml, 80 mg/ml 1 ml Antimalarials & Antiprotozoals https://www.farbefirma.org/product/artemether-injection Read More Atropine Sulphate Injection 0.6 mg/ml, 1 mg/ml 1 ml Antidotes & Detoxifying Agents https://www.farbefirma.org/product/atropine-sulphate-injection Read More Bacteriostatic Water for Injection 0.9%, 1.1% 2 ml, 10 ml, 20 ml Electrolytes & Diluents https://www.farbefirma.org/product/bacteriostatic-water-for-injection Read More Citicoline Sodium Injection 125 mg/ml, 250 mg/ml 4 ml, 5 ml CNS / Anticonvulsants / Anxiolytics https://www.farbefirma.org/product/citicoline-sodium-injection Read More Clindamycin Injection 150 mg/ml 1 ml, 2 ml, 4 ml, 6 ml, 50 ml Antibiotics https://www.farbefirma.org/product/clindamycin-injection Read More Co Trimoxazole Injection 80 mg + 400 mg 5 ml, 10 ml Antibiotics https://www.farbefirma.org/product/co-trimoxazole-injection Read More Colistimethate Sodium for Injection 1 MIU, 2 MIU Lyo Vial Antibiotics https://www.farbefirma.org/product/colistimethate-sodium-for-injection Read More 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 ... 24

Discover the best company to work for in the pharmaceutical industry. Explore job listings and job titles at Farbe Firma Pvt. Ltd. in Ankleshwar, Gujarat. Job Listings At Farbe Firma, you’re more than an employee—you are part of a mission to transform global healthcare. As a member of our team, you’ll work in state‐of‐the‐art facilities that adhere to WHO-GMP standards and partner with experts who push the boundaries of innovation in sterile injectable manufacturing. We export to over 30 countries, ensuring your work has real, positive impact on patients worldwide. We value learning, integrity, and scientific excellence, offering opportunities for growth, collaboration, and development in a culture that demands quality, but supports you every step of the way. Share Your CV and Join Farbe Firma Pvt Ltd's Growing Team of Pharmaceutical Professionals hr@farbefirma.com & info@farbefirma.com Purchase Executive View Job Purchase Manager View Job QC Micro View Job RO Operator View Job Packing Officer View Job QA Validation View Job HR Manager View Job HR Specialist View Job Jobs for Fresher View Job HR Executive View Job Ampoule Filling line Operator View Job Vial Line Operator View Job Share Your CV and Join Farbe Firma Pvt Ltd's Growing Team of Pharmaceutical Professionals hr@farbefirma.com & info@farbefirma.com

Leading WHO-GMP manufacturer of Cerebroprotein Hydrolysate for Injection . Available in 60 mg . Global exporter to Africa, CIS & Asia. Contact for CDMO & bulk supply. < Back Cerebroprotein Hydrolysate for Injection Strength: 60 mg Fill Volume: Lyo Vial Therapeutic Catagory: Other Product Name: Cerebroprotein Hydrolysate for Injection For More details please visit: https://www.farbefirma.org/products or https://www.farbefirma.org/contact Previous Next